There are currently 117 active clinical trials seeking participants for Schizophrenia research studies. The states with the highest number of trials for Autism participants are California, Florida, Texas and New York.
EPI-MINN: Targeting Cognition and Motivation - National
NCT05877716
Recruiting
The purpose of this study is to perform a practice-based research project designed to assess whether cognition and motivated behavior in early psychosis can be addressed as key treatment goals within real-world settings by using a 12-week mobile intervention program. Participants who are receiving care at coordinated specialty care (CSC) early psychosis clinics across the United States will be recruited to participate in this study. A qualifying CSC program will provide comprehensive clinical se... Read More
Gender:
All
Ages:
Between 15 years and 40 years
Trial Updated:
06/22/2023
Locations: University of Minnesota Department of Psychiatry & Behavioral Sciences, Minneapolis, Minnesota
Conditions: Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Register for Updates
Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode
NCT05890183
Recruiting
The participants in the study will receive psychiatric treatment at the UCLA Aftercare Research Program. All participants in this 12-month RCT will receive cognitive training. Half of the patients will also be randomly assigned to the aerobic exercise and strength training condition, and the other half will be randomly assigned to the Healthy Living Group condition. The primary outcome measures are improvement in cognition and level of engagement in the in-group and at-home exercise sessions. In... Read More
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
05/25/2023
Locations: UCLA Aftercare Research Program, Los Angeles, California
Conditions: Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Register for Updates
Academic-Community EPINET (AC-EPINET)
NCT04497857
Recruiting
The investigators propose to examine the effects of CSC services delivered via TH (CSC-TH) versus the standard clinic-based CSC model (CSC-SD) on engagement and outcomes in a 12-month, randomized trial.
Gender:
All
Ages:
Between 16 years and 35 years
Trial Updated:
05/16/2023
Locations: Prevention and Recovery Center for Early Psychosis, Indianapolis, Indiana +5 locations
Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features, Bipolar Disorder With Psychotic Features
Register for Updates
Sodium Nitroprusside in Early Course Schizophrenia
NCT04986072
Recruiting
Peripheral inflammation and microvascular dysfunction are central to the pathophysiology of schizophrenia (SZ). Retinal imaging allows for the accurate quantitative assessment of the condition of retinal microvessels, and early studies implicate microvascular dysfunction in SZ, but the specific pathophysiological mechanisms underlying greater length, density, capillary network and diameter are not yet entirely understood. Anti-inflammatory drug trials in SZ suggest that Early Course Schizophreni... Read More
Gender:
All
Ages:
Between 18 years and 40 years
Trial Updated:
05/12/2023
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Schizophrenia, Schizoaffective Disorder
Register for Updates
PET Imaging Study of α7 and α4β2-nAChR in Schizophrenia
NCT05462340
Recruiting
The purpose of this research is to use specialized brain imaging techniques, Positron Emission Tomography (PET) scan and Magnetic Resonance Imaging (MRI), to learn more about the brain chemistry, e.g., how neurotransmitters and receptors in the brain function in people with schizophrenia compared to healthy controls.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
05/01/2023
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Schizophrenia
Register for Updates
Synbiotic Compound to Reduce Symptoms of Schizophrenia
NCT04226898
Recruiting
The purpose of this study is to determine if taking a synbiotic supplement versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/19/2023
Locations: Sheppard Pratt Health System, Baltimore, Maryland
Conditions: Schizophrenia, Schizoaffective Disorder
Register for Updates
Brain Stimulation, Clinical Symptoms and Cognition
NCT05053451
Recruiting
The purpose of this study is to test the impact of non-invasive brain stimulation, transcranial direct current stimulation (tDCS), on auditory hallucinations, negative symptoms and cognition in schizophrenia. Clinical measures will be used to assess clinical symptoms and cognitive performance to test the hypothesis that a course of tDCS can reduce auditory hallucinations and negative symptoms in schizophrenia.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/16/2023
Locations: Imaging Research Center, Sacramento, California
Conditions: Schizophrenia
Register for Updates
Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
NCT00178932
Recruiting
The goals of this study are to replicate previous findings of genetic predictors of response to clozapine and other antipsychotic drugs.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/03/2023
Locations: Psychiatric Hospital at Vanderbilt, Nashville, Tennessee
Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Register for Updates
TMS Related Biomarker Assessments
NCT05660018
Recruiting
Patients with schizophrenia spectrum disorder (SSD) will be exposed to active and sham repetitive transcranial magnetic stimulation (rTMS) in separate sessions. SSD-related biomarkers will be assessed before and after the rTMS administration.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/30/2023
Locations: University of Maryland, Baltimore, Baltimore, Maryland
Conditions: Schizophrenia Schizoaffective, Schizophrenia
Register for Updates
Cognitive Training for Emotion Regulation in Psychotic Disorders
NCT04414215
Recruiting
The current study examines the efficacy of a cognitive training intervention for improving emotion regulation in psychotic disorders. it is hypothesized that the cognitive training program will enhance prefrontal activation, leading to enhanced emotion regulation.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
02/13/2023
Locations: University of Georgia, Athens, Georgia
Conditions: Schizophrenia, Schizo Affective Disorder
Register for Updates
Medial-prefrontal Enhancement During Schizophrenia Systems Imaging
NCT04807530
Recruiting
This randomized controlled trial in healthy controls (HC) and patients with schizophrenia (SZ) aims to examine 1) the underlying cognitive and neural cause of self-agency deficits in SZ; 2) the responsiveness to a novel navigated repetitive transcranial magnetic stimulation (nrTMS) target in the medial/superior prefrontal cortex (mPFC); and 3) how modulation of mPFC activity impacts the larger self-agency network to mediate changes in self-agency judgments. Our overall hypothesis is that increas... Read More
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
01/30/2023
Locations: UCSF, San Francisco, California
Conditions: Schizophrenia
Register for Updates
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
NCT03817502
Recruiting
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
Gender:
All
Ages:
Between 13 years and 17 years
Trial Updated:
12/15/2022
Locations: ProScience Research Group, Culver City, California +56 locations
Conditions: Schizophrenia
Register for Updates